URGN is currently covered by 2 analysts with average potential upside of $19.36 (75.98%) backed by 37 price targets and 26 ratings. Documented since 30-May-2017. Analyst's average stock valuation to be materialised ratio is 17.14% with an average time for price targets to be met of 48.25 days.
Most recent stock forecast was given by RAGHURAM SELVARAJU from HCWAINWRIGHT on 16-Feb-2023.
Highest price target for URGN is 21, Lowest price target is 8, average price target is 14.5.
Currently, out of the existing stock ratings of URGN - 3 which are a Buy (75%), 1 which are a Hold (25%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
23
$14.61 (174.14%)
1 months 11 days ago
0/2 (0%)
$27.87 (125.07%)
Hold
11
$2.61 (31.11%)
25
1 years 5 days ago
2/7 (28.57%)
$9.81 (36.75%)
104
Buy
34
$25.61 (305.24%)
40
2 years 8 days ago
0/9 (0%)
$23.21 (89.97%)
Buy
41
$32.61 (388.68%)
70
3 years 5 months 6 days ago
2/5 (40%)
$16.54 (52.12%)
89
What is URGN(UroGen Pharma Ltd) average time for price targets to be met?
Which analyst has the current highest performing score on URGN(UroGen Pharma Ltd) with a proven track record?
